Christiana Egi is the owner of the Alexis Lodge — a home to more than 20 people living with dementia. But why stop there?…
In a Scottish study, the brains of beached dolphins, whales, and porpoises showed the same biomarkers as the brain of a human with Alzheimer’s….
Eisai and Biogen’s new anti-amyloid drug Leqembi was recently approved through the FDA’s accelerated pathway. Now, it’s on the market with a price tag…
People diagnosed with cancer are less likely to develop dementia. Scientists probe the strange relationship between these diseases seeking clues for dementia prevention. Dementia…
Could getting serious about exercise really have a substantial impact on cognition as we age? Determining exactly how often someone needs to work out…
Memory loss, confusion, cognitive impairment, and brain inflammation. Those aren’t just the signs and symptoms of Alzheimer’s disease and dementia. A year after a…
Update: As of July 6, 2023, the drug has full, traditional FDA approval. Today, the Food and Drug Administration approved Leqembi (generic name lecanemab), a…
Drugmakers Eisai and Biogen took their anti-amyloid Alzheimer’s treatment, lecanemab, to the finish line. By clearing amyloid plaques in the brains of people with…
Lecanemab, Eisai and Biogen’s experimental anti-amyloid Alzheimer’s drug, which recently wrapped its Phase 3 clinical trials, continues to make the news. Some of these…
The United States imposed a blockade against Cuba in 1961, and currently there isn’t much collaboration — or even, much communication — about medical…
The majority of experimental Alzheimer’s drugs are being designed to halt the progression of the disease — a strategy which so far has yielded…
The approval of the controversial anti-amyloid drug Aduhelm last year marked a major milestone for Alzheimer’s research — it became the first new drug…
Could insulin treat Alzheimer’s the same way it treats diabetes? Evidence shows Alzheimer’s might be more similar to a metabolic disorder, like diabetes, than…
New data presented at CTAD about an existing agitation drug, brexpiprazole, in trials for patients with Alzheimer’s, bears potential good news when it comes…
Much anticipated Phase 3 data for Alzheimer’s drug lecanemab was presented at CTAD in 2022, showing the drug is as safe as the placebo…